T3N0M0声门型鳞状细胞癌单纯根治性放疗与放化疗的生存结局比较
基于美国国家癌症数据库分析3785例T3N0M0声门型鳞状细胞癌患者,比较单纯放疗与放化疗的生存结局。年龄≥70岁及有合并症者接受化疗的几率较低(OR分别为0.30和0.48)。放化疗组5年总生存率高于单纯放疗组(58.0% vs 33.8%),在年龄<70岁且无合并症患者中差异持续存在(66.7% vs 51.0%)。
要点
- 放化疗组5年总生存率58.0%,单纯放疗组33.8%,放化疗组更高。
- 年龄<70岁且无合并症者中,放化疗组5年总生存率66.7%,单纯放疗组51.0%。
- 年龄≥70岁及有合并症者接受化疗的几率较低(OR 0.30和0.48)。
核心结论
- 放化疗组总生存率高于单纯放疗组,即使在控制年龄和合并症后仍如此。
- 作者认为,对于T3N0M0声门型鳞状细胞癌患者,省略化疗的单纯放疗是不恰当的。
研究设计与样本
- 研究为生存分析,数据来源于美国国家癌症数据库(National Cancer Database)。
- 纳入3785例T3N0M0声门型鳞状细胞癌患者,比较单纯放疗与放化疗。
主要发现
- 年龄≥70岁患者接受化疗的OR为0.30(95% CI 0.25-0.37),有合并症患者接受化疗的OR为0.48(95% CI 0.31-0.76)。
- 放化疗组5年总生存率为58.0%(95% CI 55.8%-60.0%),单纯放疗组为33.8%(95% CI 30.3%-37.2%)。
- 在年龄<70岁且无合并症患者中,放化疗组5年总生存率为66.7%(95% CI 64.0%-69.3%),单纯放疗组为51.0%(95% CI 44.5%-57.0%)。
临床怎么用
- 作者认为,对于T3N0M0声门型鳞状细胞癌患者,省略化疗的单纯放疗是不恰当的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Given the poor lymphatics of the glottis, we evaluated omission of chemotherapy in patients treated definitely for T3N0M0 squamous cell carcinoma (SCC) of the glottis. METHODS: We performed survival analysis of patients with T3N0M0 SCC of the glottis identified in the National Cancer Database treated with radiation alone versus chemoradiation. RESULTS: A total of 3785 patients were identified. Patients age ≥70 and those with comorbidities were less likely to receive chemotherapy (odds ratio [OR] 0.30, 95% CI [0.25-0.37] and 0.48 [0.31-0.76], respectively). Five-year OS was lower in patients treated with radiation versus chemoradiation (33.8% [30.3%-37.2%] vs. 58.0% [55.8%-60.0%]). In patients <70 with no comorbidities this difference persisted (51.0% [44.5%-57.0%] versus 66.7% [64.0%-69.3%]). CONCLUSION: Overall survival was higher in patients treated with chemoradiation compared to radiation alone, even when controlling for age and comorbidities. Radiotherapy with chemotherapy omission is not appropriate in patients with T3N0M0 SCC of the glottis.
引用
- Rock CB, Hutten RJ, Weil CR, et al. Survival outcomes for patients with T3N0M0 squamous cell carcinoma of the glottis treated with definitive radiation alone versus chemoradiation. Head Neck. 2022. PMID: 36433726. doi:10.1002/hed.27255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。